Fig 1: Expression of SPP1 and PKCα was increased in SCs after median nerve injury in the human specimens. a Immunofluorescence staining of SPP1 (red), PKCα (red) and S100β (green) in health median nerve and distal median nerve stumps at 5 days after injury. Scale bar, 200 and 50 μm. b, c Relative mRNA expression of SPP1 (b) and PKCα (c) in injured median nerve at 0, 5, 8, 13 h, 7, and 14 days of six independent samples by real-time qPCR. d–f Western blot analysis of SPP1 and PKCα in injured median nerve at 0, 5, 8, 13 h, 7, and 14 days after injury. Repeated for three-time. d Representative blot results. e, f Quantification of the relative expression of proteins in (d). Data are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001
Fig 2: CD44 and αvβ3 were indispensable for SPP1 mediated activation of PKCα and its downstream pathway. a Real-time qPCR determined the expression of PKCα in SCs transfected with si-CD44, si-β3, or si-Control combined with or without rOPN (50 nM) medium. b–f Western blot analysis of PKCα and its downstream cytokines expression levels after siRNA transfection and rOPN treatment in SCs. GAPDH was used as a loading control. b Representative blot. c–f Quantification of the relative expression of proteins. Data were obtained from three independent experiments and presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001
Fig 3: The cardiac fibroblast (CF) secretome increases neonatal rat ventricular myocyte (NRVM) size. A, Schematic of conditioned medium (CM) treatment of NRVMs (48 hours treatment with conditioned media from CFs). B, Coulter counter measurements of NRVMs treated for 48 hours with CM from CFs with or without 3 μmol/L SD208 to inhibit effects caused by TGFβ1 (transforming growth factor β 1) (N=CM from 3 CF isolations, 4 rats pooled per isolation, error bars show mean and SEM, 1‐way ANOVA, *P≤0.05, **P≤0.01). C, Coulter counter measurements of NRVM volume when treated with different concentrations of osteopontin (OPN), insulin growth factor 1 (IGF‐1), or phenylephrine (PE) (10 μmol/L), (N=2 isolations of NRVMs, N=3 for controls [same controls used for OPN and IGF‐1 treatment], error bars show SD, 1‐way ANOVA, significance compared with untreated, *P≤0.05, **P≤0.01). D, Schematic of CF signaling to NRVMs to induce hypertrophy through IGF‐1 signaling.
Fig 4: Expression of endogenous osteopontin (OPN) and Beclin 1 in different cell types of rat brain at 24 h after SAH. Double immunofluorescence staining for endogenous OPN (A) or Beclin 1 (B) in neurons (NeuN, green), astrocytes (GFAP, green) and microglia (IBA‐1, green) in the left basal cortex of rat brain at 24 h after SAH. Nuclei are stained with DAPI (blue). The red box in the brain slice image indicates the area observed. n = 3 per group. Scale bar = 50 μm
Fig 5: SPP1 promoted SCs proliferation and inhibited the apoptosis through PKCα. a Real-time qPCR and Western blot tested the efficiency of SPP1-siRNAs (si-SPP1) in SCs. b Real-time qPCR and Western blot examined the overexpression of SPP1 (GV146-SPP1) in SCs. c, e EdU analysis of the proliferation rate of SCs treated by si-SPP1, si-SPP1 + PMA, and si-Control (c), and quantification data was shown (e). d, f The apoptosis of SCs was detected by flow cytometry (d), and the apoptosis rate was quantified (f). g, i EdU analyzed the proliferation rate of SCs treated by GV146-SPP1, GV146-SPP1 + Gö6976, and GV146 (g). The proliferation of fold change was quantified (i). h, j Flow cytometry tested the apoptosis rate of SCs. k–m Western blot analysis of PKCα, p-ERK, ERK, Bcl-2, Bax, cleaved Caspase-3, and Caspase-3 protein expression following si-SPP1, si-SPP1 + PMA transfection and treatment in SCs, or following GV146-SPP1, GV146-SPP1 + Gö6976 transfection and treatment in SCs, respectively. Representative blot (k) and quantification of the related expression of proteins (l, m) were presented. Scale bar, 100 μm. Data were shown as mean ± SEM from three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001
Supplier Page from R&D Systems, a Bio-Techne Brand for Osteopontin/OPN Protein
Available conjugates: Sizes Available: 50 ug